This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.
In this report, we present an update of the 2020 primary systematic review, to take into account more recent evidence on the efficacy, effectiveness and safety of newer and/or enhanced seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals aged 18 years and over.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Every month ECDC provides detailed epidemiological overview of the worldwide transmission of chikungunya in its weekly threat report (Communicable Diseases Threat Report).